[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-hemorrhage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-hemorrhage":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,88],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100643163","phase-3-nebulized-versus-intravenous-tranexamic-acid-for-the-management-of-hemoptysis-100643163",false,"NCT07641946","Nebulized Versus Intravenous Tranexamic Acid for the Management of Hemoptysis","Nebulized Versus Intravenous Tranexamic Acid for the Management of Hemoptysis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥18 years.\n* Presenting with active hemoptysis 24-48 hours prior to enrollment, or ongoing bleeding at presentation.\n* Patients presented with mild to moderate hemoptysis, defined as \\\u003C100 mL\u002Fday, or with clinically stable non-massive hemoptysis without evidence of respiratory or hemodynamic compromise.\n* Hemodynamically stable at presentation defined as systolic blood pressure ≥90 mmHg without vasopressor support, heart rate ≤120 beats\u002Fmin, and absence of clinical signs of shock or ongoing hemodynamic deterioration.\n* Patients able to maintain a patent airway, tolerate nebulized therapy, and have no immediate contraindications (e.g., severe bronchospasm, impaired consciousness with aspiration risk, or need for urgent intubation), ensuring safe and effective drug delivery.\n* Written informed consent obtained from the patient.\n\nExclusion Criteria:\n\n* Massive or life-threatening hemoptysis defined as expectoration of \\>100 mL of blood within 24 hours, or any volume associated with impaired gas exchange, airway obstruction, or hemodynamic instability requiring urgent intervention (e.g., bronchoscopy, bronchial artery embolization, endotracheal intubation, or surgery).\n* Hemodynamic instability which defined as SBP \\\u003C90 mmHg or MAP \\\u003C65 mmHg, need for vasopressor support, or clinical evidence of end-organ hypoperfusion or shock.\n* Respiratory failure requiring immediate invasive mechanical ventilation.\n* Patients known with hypersensitivity to tranexamic acid.\n* Patients receiving ongoing anticoagulant therapy that can interfere with the antifibrinolytic effect of tranexamic acid.\n* Patients with known bleeding disorders, severe coagulopathy, or thrombocytopenia (platelet count \\\u003C50,000\u002Fmm³).\n* Patients with severe renal impairment (e.g., estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m² or requiring dialysis).\n* Patients with active thromboembolic disease or a recent history (within the past 3-6 months) of deep vein thrombosis, pulmonary embolism, ischemic stroke, or myocardial infarction.\n* Pregnancy or lactation.","ALL","18 Years",{"count":19,"type":20},170,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This clinical trial aims to compare two different ways of giving a medication called tranexamic acid to patients who are coughing up blood (a condition known as hemoptysis). Coughing up blood can be a serious medical issue that needs to be stopped quickly. Tranexamic acid is a well-known medication that helps blood to clot and stops bleeding.\n\nUsually, this medication is given through an intravenous (IV) line directly into a vein. However, doctors are now studying if giving the medication through a breathing mask (nebulizer) might work just as well or better. A nebulizer changes the liquid medicine into a fine mist so the patient can breathe it directly into their lungs, targeting the exact area where the bleeding is happening.\n\nTo find out which method is better, researchers will randomly assign 170 adult patients who come to the hospital coughing up blood into two equal groups:\n\nGroup 1: Will receive the tranexamic acid medication inhaled through a nebulizer mask.\n\nGroup 2: Will receive the tranexamic acid medication through a standard IV line.\n\nThe main goal of the study is to see which treatment is more successful at completely stopping the bleeding within 24 hours. Researchers will also closely monitor the patients to see how quickly the bleeding stops, how long patients need to stay in the hospital, and if there are any side effects from either treatment method.",[26,27],"Hemoptysis","Pulmonary Hemorrhage",[29,30,31,32,33,34,35],"Tranexamic Acid","Nebulized Tranexamic Acid","Intravenous Tranexamic Acid","Antifibrinolytic Agents","Inhalational Therapy","Active Bleeding","Airway Management","NOT_YET_RECRUITING","2026-06-08",{"date":39,"type":40},"2026-06-11","ACTUAL",{"date":42,"type":20},"2026-07",{"date":44,"type":20},"2027-08",{"name":46,"class":47},"Assiut University","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":56,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":69,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100613980","characterization-of-extracellular-vesicles-from-the-cord-blood-of-extremely-preterm-new-borns-and-their-correlation-with-severe-morbidity-and-mortality-100613980","NCT07273643","Characterization of Extracellular Vesicles From the Cord Blood of Extremely Preterm New Borns and Their Correlation With Severe Morbidity and Mortality","VEEP","Inclusion Criteria:\n\n* Mother over 18 years old, able to speak and understand French\n* Newborn less than 28 weeks of gestation, born and hospitalized at Montpellier University Hospital\n* Umbilical cord venous blood collected immediately after birth (from the segment between the cord clamp and the placenta), with a volume of 10 ml (which can be reduced to 3 ml if collection is difficult) into an EDTA tube.\n* Parental non-opposition to the study obtained before sample collection\n\nExclusion Criteria:\n\n* Stillborn infant\n* Handling failure: failure to collect the sample or start the first centrifugation more than 3 hours after birth\n* General regulatory criteria: failure to obtain parental non-opposition, lack of social security coverage, individuals under legal guardianship, or participation in another ongoing research study with an active exclusion period","0 Days","3 Months",{"count":58,"type":20},30,"OBSERVATIONAL","This study aims to understand the role of extracellular vesicles (EVs) in extremely premature infants, those born before 28 weeks of gestation. EVs are tiny particles released by cells that carry important information about the body's condition. In extremely premature infants, blood vessels may not function properly, leading to serious health problems such as bleeding in the brain, lung injury, or severe infections.\n\nResearchers believe that analyzing EVs in the umbilical cord blood of these infants may help predict which babies are at higher risk of developing these complications. By studying the size, number, and type of EVs, the team hopes to identify early markers that can guide doctors in providing better care.\n\nThe study will collect cord blood from 30 eligible infants born at the CHU of Montpellier. Blood samples will be processed to isolate platelet-poor plasma, which contains EVs. This plasma will be stored in a biobank, allowing future research on EVs and their role in extreme prematurity. EVs will then be analyzed in the laboratory to assess their characteristics and any links to severe health issues.\n\nThe findings from this study could improve understanding of circulatory problems in extremely premature infants, help identify early predictors of severe complications, and inform better monitoring and treatment strategies. The creation of a plasma biobank also provides a valuable resource for future research to enhance care and outcomes for this vulnerable population.",[62,27,63,64,65,66,67,68],"Intraventricular Hemorrhage","Death","ELGAN (22-28SA)","Bronchopulmonary Dysplasia (BPD)","Shock","Extracellular Vesicles","Enterocolitis, Necrotizing",[70,71,72,73,74,75,76],"ELGAN","Extremely Low Gestational Age Newborn (ELGAN)","Extracellular vesicles","EVs","Intraventricular hemorrage","Pulmonary hemorrhage","Bronchopulmonary Dysplasia","RECRUITING","2026-02-19",{"date":80,"type":40},"2026-02-23",{"date":82,"type":40},"2026-01-13",{"date":84,"type":20},"2027-10-13",{"name":86,"class":47},"University Hospital, Montpellier",1,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":21,"phases":96,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":87},"100443397","phase-3-a-randomized-controlled-trial-of-inhaled-tranexamic-acid-for-the-treatment-of-pulmonary-hemorrhage-in-cancer-patients-100443397","NCT05053867","A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients","Inclusion Criteria:\n\n1. Age \\> 18 years old\n2. Have a diagnosed hematological malignancy\n3. Are actively receiving mechanical ventilation\n4. Have evidence of pulmonary hemorrhage as defined by either\n\n   1. Persistently bloody secretions upon endotracheal tube suctioning, or\n   2. Evidence of diffuse alveolar hemorrhage by bronchoscopic examination\n5. Signed informed consent by patient or if the subject lacks decision-making capacity, the subject's legally authorized representative\n\n2.3.2 Exclusion Criteria\n\nPatients excluded from participation in the study if any of the following criteria are met:\n\n1. Presence of a Do Not Resuscitate (DNR), no escalation of care or comfort care order at the time of screening\n2. Expected survival \\\u003C 48 hours\n3. Evidence of nasal or oral spillage likely to be the cause of bloody secretions\n4. Patients requiring 100% FIO2\n5. Known hypersensitivity to tranexamic acid\n6. Treatment with inhaled tranexamic acid prior to screening\n7. Acquired defective color vision\n8. Subarachnoid hemorrhage\n9. Deep Venous or arterial thrombus diagnosed within the previous 3 months\n10. Seizure disorder on active anti-epileptic therapies\n11. Hypersensitivity to tranexamic acid or any of the ingredients\n12. Pregnant women will not be eligible and have a negative pregnancy test prior to entering study\n13. Patient receiving concurrent anti-fibrinolytic therapy\n14. Confirmed active COVID-19 infection",{"count":95,"type":20},60,[23],"This is a drug study that will examine if inhaled tranexamic acid can improve mortality in patients with cancer-related pulmonary hemorrhage and respiratory failure as compared to usual care.",[27,99],"Cancer","2026-01-12",{"date":102,"type":40},"2026-01-14",{"date":104,"type":40},"2022-10-14",{"date":106,"type":20},"2027-07-31",{"name":108,"class":47},"M.D. Anderson Cancer Center"]